Cargando…

Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome

Rationale: Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare but comprise a genetically heterogeneous patient group. RNA sequencing linked to the underlying genetic architecture can be used to better understand the underlying pathology by identifying key signaling pathways and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhodes, Christopher J., Otero-Núñez, Pablo, Wharton, John, Swietlik, Emilia M., Kariotis, Sokratis, Harbaum, Lars, Dunning, Mark J., Elinoff, Jason M., Errington, Niamh, Thompson, A. A. Roger, Iremonger, James, Coghlan, J. Gerry, Corris, Paul A., Howard, Luke S., Kiely, David G., Church, Colin, Pepke-Zaba, Joanna, Toshner, Mark, Wort, Stephen J., Desai, Ankit A., Humbert, Marc, Nichols, William C., Southgate, Laura, Trégouët, David-Alexandre, Trembath, Richard C., Prokopenko, Inga, Gräf, Stefan, Morrell, Nicholas W., Wang, Dennis, Lawrie, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427383/ https://www.ncbi.nlm.nih.gov/pubmed/32352834 http://dx.doi.org/10.1164/rccm.202003-0510OC

Ejemplares similares

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2021)

Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2022)

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
por: Rhodes, Christopher J., et al.
Publicado: (2017)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach
por: Errington, Niamh, et al.
Publicado: (2021)

Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
por: Sofianopoulou, Eleni, et al.
Publicado: (2020)

Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2021)

Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy
por: Wilkins, Martin R., et al.
Publicado: (2021)

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
por: Hadinnapola, Charaka, et al.
Publicado: (2015)

Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension
por: Jones, Rowena J., et al.
Publicado: (2022)

Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
por: Peacock, Andrew J., et al.
Publicado: (2020)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
por: Gräf, Stefan, et al.
Publicado: (2018)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension
por: Robertson, Lucy, et al.
Publicado: (2022)

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023)

Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2020)

Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension
por: Hernández-Sánchez, Jules, et al.
Publicado: (2017)

Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at follow‐up
por: Rodgers, Matthew S., et al.
Publicado: (2022)

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
por: Bunclark, Katherine, et al.
Publicado: (2021)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

Screening strategies for pulmonary arterial hypertension
por: Kiely, David G, et al.
Publicado: (2019)

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension
por: Condliffe, Robin, et al.
Publicado: (2012)

Balloon pulmonary angioplasty outcomes in patients previously treated by pulmonary endarterectomy surgery are inferior to those of inoperable patients
por: Kirkby, Louise C., et al.
Publicado: (2023)

EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study
por: Lewis, Robert A., et al.
Publicado: (2021)

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
por: Dunmore, Benjamin J., et al.
Publicado: (2013)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood
por: Ormiston, Mark L., et al.
Publicado: (2015)

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
por: Newnham, Michael, et al.
Publicado: (2019)

Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis
por: Owen, Nicola E., et al.
Publicado: (2020)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study
por: Hagan, Guy, et al.
Publicado: (2011)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

First Genotype–Phenotype Study in TBX4 Syndrome: Gain-of-Function Mutations Causative for Lung Disease
por: Prapa, Matina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7f67hbpkg7679ec5gjugckm1ce